The American Society of Tropical Medicine and Hygiene has waived the Open Access fee for this article due to the ongoing COVID-19 pandemic.
Khoury DS , Cromer D , Reynaldi A , Schlub TE , Wheatley AK , Juno JA , Subbarao K , Kent SJ , Triccas JA , Davenport MP , 2021. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 27: 1205–1211.
Caribbean Public Health Agency , 2021. COVID-19 Vaccine Update Supplement. Port of Spain, Trinidad and Tobago, West Indies: Caribbean Public Health Agency. Available at: https://carpha.org/Portals/0/Documents/COVID-19%20Vaccine%20Updates/CARPHA%20COVID-19%20Vaccine%20Update%20042%20November%201,%202021.pdf.
Christie CDC , Thompson T , Webster-Kerr K , 2020. COVID-19 war games in the Caribbean: round one. Pandemic Case Stud Opin 1: 68–76.
Du L , Yang Y , Zhang X , 2021. Neutralizing antibodies for the prevention and treatment of COVID-19. Cell Mol Immunol 18: 2293–2306.
Lukaszuk K , Kiewisz J , Rozanska K , Dabrowska M , Podolak A , Jakiel G , Woclawek-Potocka I , Lukaszuk A , Rabalski L , 2021. Usefulness of IVD kits for the assessment of SARS-CoV-2 antibodies to evaluate the humoral response to vaccination. Vaccines (Basel) 9: 840.
Buss LF et al.2021. Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. Science 371: 288–292.
Eyre DW et al.2021. Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status. Clin Microbiol Infect 27: 1516.e7–1516.e14.
Anderson M , Stec M , Rewane A , Landay A , Cloherty G , Moy J , 2021. SARS-CoV-2 antibody responses in infection-naive or previously infected individuals after 1 and 2 doses of the BNT162b2 vaccine. JAMA Netw Open 4: e2119741.
Röltgen K et al.2020. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Sci Immunol 5: eabe0240.
Folegatti PM et al.2020. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 396: 467–478.
Voysey M et al.2021. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 397: 881–891.
Flaxman A et al.2021. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet 398: 981–990.
Perkmann T , Perkmann-Nagele N , Koller T , Mucher P , Radakovics A , Marculescu R , Wolzt M , Wagner OF , Binder CJ , Haslacher H , 2021. Anti-spike protein assays to determine SARS-CoV-2 antibody levels: a head-to-head comparison of five quantitative assays. Microbiol Spectr 9: e00247–e21.
- Search Google Scholar
- Export Citation
Perkmann T Perkmann-Nagele N Koller T Mucher P Radakovics A Marculescu R Wolzt M Wagner OF Binder CJ Haslacher H 2021. Anti-spike protein assays to determine SARS-CoV-2 antibody levels: a head-to-head comparison of five quantitative assays. Microbiol Spectr 9: e00247– e21.
Feng S , Phillips DJ , White T , Sayal H , Aley PK , Bibi S , Dold C , Fuskova M , Gilbert SC , Hirsch I , 2021. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med 27: 2032–2040.